<DOC>
	<DOCNO>NCT00121277</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vorinostat capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may also stop growth tumor cell block enzymes need cell growth . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vorinostat capecitabine treat patient unresectable metastatic solid tumor .</brief_summary>
	<brief_title>Vorinostat Capecitabine Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose vorinostat ( SAHA ) capecitabine patient metastatic unresectable solid tumor . - Determine safety tolerability regimen patient . Secondary - Correlate clinical effect pharmacokinetic effect regimen patient . OUTLINE : This dose-escalation , multicenter study . Patients receive oral vorinostat ( SAHA ) twice daily oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day least 6 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 course beyond documentation CR . Patients achieve partial response receive 2 course beyond documentation best response . Cohorts 3-6 patient receive escalate dos SAHA capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 12 patient treated MTD . After completion study treatment , patient follow 3-4 week every 3 month thereafter . PROJECTED ACCRUAL : Approximately 18-30 patient accrue study within 6-10 month .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor Metastatic unresectable disease Standard curative palliative measure exist longer effective Patients receive prior radiotherapy must measurable disease outside previously irradiated field OR disease progression prior radiotherapy No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow oral medication No clinical radiological diagnosis bowel obstruction No ongoing active infection No history allergic reaction attribute compound similar chemical biological composition suberoylanilide hydroxamic acid agent use study No known dihydropyrimidine dehydrogenase deficiency No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior fluorouracil allow No prior capecitabine Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy recover No prior radiotherapy &gt; 40 % bone marrow Surgery At least 4 week since prior surgery recover Other At least 2 week since prior valproic acid No concurrent investigational agent No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>